Phase Iii Tropics-04 Trial: Sacituzumab Govitecan Vs Treatment Of Choice In Advanced Muc

Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC

Final OS analysis of sacituzumab govitecan in TROPiCS-02

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously tre...

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope Rugo

Medicine Matters oncology

ASCENT trial: sacituzumab govitecan for TNBC

Sacituzumab Govitecan Versus Platinum-Based Chemotherapy for Second-Line mUC

GU Oncology Now

The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia

Medicine Matters oncology

TROPHY-U-01 Cohort 3: sacituzumab govitecan + pembrolizumab for patients with mUC

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens...

Study of sacituzumab govitecan for triple-negative breast cancer

Dana-Farber Cancer Institute

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metast...

Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

Potential of sacituzumab govitecan plus pembrolizumab demonstrated in mUC patients | Petros Grivas

Medicine Matters oncology

TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

Sacituzumab Govitecan in mTNBC

Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan With Kevin Kalinsky

Oncology Data Advisor

ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer